Robert A. Figlin, MD, Discusses 2020 Treatment Advances for Patients with RCC
The expert from Cedars-Sinai Cancer spoke about the continued integration of immunotherapy-based combination regimens, and the importance of utilizing the multidisciplinary care team to mitigate any possible toxicities that may arise.
The use of immunotherapy and immunotherapy-based combination regimens have demonstrated significant benefits for patients with renal cell carcinoma (RCC).
Longer term follow-up for treatment regimens such as nivolumab (Opdivo) and ipilumumab (Yervoy) or pembrolizumab (Keytruda) and axitinib (Inlyta) have shown deeper and sustained responses for patients with untreated metastatic disease.
In an interview with CancerNetwork®, Robert A. Figlin, MD, Deputy Director of Cedars Sinai Cancer, discussed the treatment advances for patients with RCC that were made over the last year, the importance of the multidisciplinary team when implementing care, and the potential to cure patients in the near future.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
